Albuterol

MannKind stunned the diabetic community on Tuesday after reporting in a regulatory filing that it did not foresee entering into a co-marketing agreement for its lead product candidate, the inhaled insulin product AFRESA, before the end of 2009. Prudent business decision by management -- or a sign of Big Pharma's reluctance to invest in inhaled insulin technologies? The company burned through more than $1.4 billion before receiving welcome word...